World Equity Group Inc. Has $1.26 Million Stake in Johnson & Johnson $JNJ

World Equity Group Inc. lessened its position in Johnson & Johnson (NYSE:JNJ) by 35.6% in the third quarter, HoldingsChannel.com reports. The fund owned 6,784 shares of the company’s stock after selling 3,756 shares during the period. World Equity Group Inc.’s holdings in Johnson & Johnson were worth $1,258,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of JNJ. Heck Capital Advisors LLC lifted its holdings in Johnson & Johnson by 5.3% during the 3rd quarter. Heck Capital Advisors LLC now owns 2,942 shares of the company’s stock valued at $545,000 after purchasing an additional 147 shares during the last quarter. MASTERINVEST Kapitalanlage GmbH grew its stake in shares of Johnson & Johnson by 18.5% in the third quarter. MASTERINVEST Kapitalanlage GmbH now owns 18,242 shares of the company’s stock valued at $3,382,000 after acquiring an additional 2,845 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in Johnson & Johnson by 1.3% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 571,211 shares of the company’s stock worth $105,914,000 after acquiring an additional 7,577 shares during the period. Kesler Norman & Wride LLC increased its stake in Johnson & Johnson by 266.4% in the third quarter. Kesler Norman & Wride LLC now owns 52,051 shares of the company’s stock valued at $9,651,000 after acquiring an additional 37,844 shares during the last quarter. Finally, Narwhal Capital Management increased its position in Johnson & Johnson by 19.5% during the 3rd quarter. Narwhal Capital Management now owns 96,371 shares of the company’s stock worth $17,869,000 after purchasing an additional 15,755 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Delaware’s top court reduced part of a $1 billion damages award tied to J&J’s 2019 Auris Health deal, ordering a recalculation that should lower the company’s potential payout and reduce legal overhang on the balance sheet. Johnson & Johnson’s $1 billion loss from robotics takeover reduced by Delaware top court
• Positive Sentiment: J&J reported strong long-term results for Rybrevant in RAS/BRAF wild-type metastatic colorectal cancer at ASCO — a commercial and pipeline positive that supports oncology revenue upside. Johnson & Johnson Therapy Delivers Strong Results In Colorectal Cancer Trial
• Positive Sentiment: J&J’s MedTech unit shows momentum from cardiovascular strength and new product rollouts, helping offset headwinds and supporting near-term organic growth expectations. What’s Powering J&J’s MedTech Growth Ahead of Q4 Release?
• Neutral Sentiment: J&J will report quarterly results this week; investors may reprice shares on guidance, Q4 results and management commentary. (Prior quarter showed an EPS beat.) Johnson & Johnson (JNJ) Projected to Post Quarterly Earnings on Wednesday
• Neutral Sentiment: Management’s presentation transcript from the J.P. Morgan Healthcare Conference is available for review; investors will parse remarks for margin, pipeline and capital allocation signals. Johnson and Johnson (JNJ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Investor commentary and quarter-review pieces explain what drove J&J in Q4 (market momentum, product mix) — useful context but less likely to move the stock than fresh earnings or legal rulings. Here’s What Lifted Johnson & Johnson (JNJ) in Q4
• Negative Sentiment: MedTech growth still faces geographic pressure (notably China), which management flagged could linger into the next quarter and temper upside from product momentum. What’s Powering J&J’s MedTech Growth Ahead of Q4 Release?

Analysts Set New Price Targets

Several analysts have recently weighed in on JNJ shares. Royal Bank Of Canada set a $240.00 price target on Johnson & Johnson in a report on Wednesday, December 17th. Barclays boosted their target price on shares of Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a report on Tuesday, December 30th. Argus set a $210.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 15th. Bank of America boosted their target price on Johnson & Johnson from $204.00 to $220.00 and gave the company a “neutral” rating in a research report on Monday, December 15th. Finally, Scotiabank began coverage on shares of Johnson & Johnson in a report on Thursday, November 13th. They set a “sector outperform” rating and a $230.00 price objective for the company. Four equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $213.33.

Johnson & Johnson Trading Up 1.9%

NYSE:JNJ opened at $213.78 on Wednesday. The company has a market cap of $515.06 billion, a P/E ratio of 20.64, a P/E/G ratio of 2.15 and a beta of 0.34. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $215.18. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The stock’s fifty day moving average price is $203.88 and its two-hundred day moving average price is $185.81.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 14th. The company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.76 by $0.04. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $23.99 billion during the quarter, compared to analyst estimates of $23.73 billion. During the same quarter in the previous year, the firm earned $2.42 EPS. The company’s quarterly revenue was up 6.8% compared to the same quarter last year. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.